Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mizner Bioscience is a private U.S. animal health company focused on discovering, developing, and commercializing veterinary pharmaceuticals and supplements for companion animals and horses. The company describes its strategy as "discover the overlooked," emphasizing improved delivery systems, dosage forms, new indications for proven therapies, and affordability. Its visible commercial portfolio includes generic clomipramine hydrochloride tablets for separation anxiety in dogs, along with branded nutritional products such as Prolumo and Balance GI. In addition to product commercialization, the company markets capabilities around regulatory navigation and launch strategy for animal health products. Overall, Mizner Bioscience appears to be a small, commercially oriented specialty veterinary company rather than a human therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mizner Bioscience.